[Effect of psychotropic drugs on activity of anticonvulsants in maximal electroshock test]

Insights

Psychotropic drugs did not decrease anticonvulsant effects in mice. Researchers identified rational combinations, like phenobarbital with piracetam, enhancing anticonvulsant activity and reducing toxicity.

Area of Science:

  • Neuropharmacology
  • Drug Interactions
  • Epilepsy Research

Context:

  • Investigating the impact of psychotropic medications on anticonvulsant efficacy.
  • Utilizing the maximal electroshock (ME) test in white mice as a model.
  • Assessing interactions between established anticonvulsants and various psychotropic agents.

Purpose:

  • To determine if psychotropic drugs alter the pharmacological properties of anticonvulsants.
  • To identify synergistic or non-detrimental combinations of anticonvulsants and psychotropic drugs.
  • To establish criteria for rational drug combinations based on efficacy and toxicity.

Summary:

  • Evaluated the combined effects of phenobarbital, diphenin, carbamazepine, and hexamidine with psychotropic drugs (piracetam, aminalon, amitriptyline, imizine, levomepromazine, lithium oxybutyrate) in the ME test.
  • Found no instances where psychotropic drugs diminished the primary anticonvulsant effect.
  • Identified rational combinations that either enhanced anticonvulsant activity or maintained/reduced toxicity.

Impact:

  • Provides a foundation for rational polypharmacy in epilepsy management.
  • Highlights specific psychotropic drug combinations that can be safely co-administered with anticonvulsants.
  • Offers insights into optimizing treatment strategies for patients with comorbid epilepsy and psychiatric conditions.

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...